The bipartisan leadership of the Senate Finance Committee released a plan to tackle drugs costs that looks to go after but not completely gut the pharmacy benefits management industry.
The 20 April framework, which Sens. Ron Wyden, D-Ore., and Mike Crapo, R-Idaho, plan to use as the basis for proposed legislation, adds further momentum to the Congressional push to tackle drug costs by going after intermediary players in the supply chain. The Senate HELP Committee, the Senate Commerce, Science and Transportation Committee, the House Energy and Commerce and the House Oversight committees have all signaled interest in working on the topic this year
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?